The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome...
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
About this item
Full title
Author / Creator
Del Re, Marzia , Crucitta, Stefania , Paolieri, Federico , Cucchiara, Federico , Verzoni, Elena , Bloise, Francesco , Ciampi, Raffaele , Mercinelli, Chiara , Capuano, Annalisa , Sportiello, Liberata , Martinetti, Antonia , Procopio, Giuseppe , Galli, Luca , Porta, Camillo , Bracarda, Sergio and Danesi, Romano
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Despite the increasing number of treatment options, reliable prognostic/predictive biomarkers are still missing for patients affected by metastatic clear cell renal cell carcinoma (mccRCC). Methods Patients with mccRCC undergoing standard first line treatment were enrolled. Blood (12 ml) was drawn at treatment baseline and circulating fr...
Alternative Titles
Full title
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fef037278a2f4851b867577c0a56cf60
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fef037278a2f4851b867577c0a56cf60
Other Identifiers
ISSN
1479-5876
E-ISSN
1479-5876
DOI
10.1186/s12967-022-03557-7